Natalizumab and Chronic Inflammation

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Collaborator: Biogen
• Treatments: Natalizumab

Criteria

Inclusion Criteria:

1. multiple sclerosis

2. clinical eligibility to treatment with Natalizumab

3. no previous exposure to Natalizumab treatment

Exclusion Criteria:

1. inability to perform an MRI with contrast

2. inability to undergo a paper-pencil questionnaires and blood work